<DOC>
	<DOCNO>NCT02678000</DOCNO>
	<brief_summary>This randomize , double-blind , parallel group , placebo-controlled study , two sequential part evaluate renal safety , tolerability pharmacokinetics LHW090 patient moderately impaired renal function .</brief_summary>
	<brief_title>Study Safety , Tolerability , Pharmacokinetics LHW090 Patients With Moderately Impaired Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Inclusion Criteria ( Parts ) : Written inform consent must obtain assessment perform . Male female patient , age 40 85 year age ( inclusive ) stable ( least 1 month ) dose angiotensin receptor blocker ( ARB ) stable moderately impaired renal function , define eGFR 3059 mL/min/1.73m^2 ( inclusive ) use 4 variable MDRD Study equation least 3 month . At screening , vital sign ( systolic diastolic blood pressure pulse rate ) assess sit position patient rest least five minute , three minute stand position . Sitting vital sign within follow range : oral body temperature 35.037.5 °C systolic blood pressure , 100170 mm Hg diastolic blood pressure , 50100 mm Hg pulse rate , 50 95 bpm Patients exclude stand vital sign ( relative sit ) show finding , opinion Investigator , associate clinical manifestation postural hypotension ( i.e . absence cause ) . The Investigator carefully consider enrol patient either &gt; 20 mm Hg decrease systolic &gt; 10 mm Hg decrease diastolic blood pressure , accompany &gt; 20 bpm increase heartrate ( compare stand sit result ) . Patients must weigh least 50 kg participate study , must body mass index ( BMI ) within range 18 38 kg/m^2 . BMI = Body weight ( kg ) / [ Height ( ) ] ^2 . Able communicate well investigator , understand comply requirement study . Exclusion criterion : History angioedema , drugrelated otherwise , report patient . Use angiotensin convert enzyme inhibitor ( ACE inhibitor ) , mineralocorticoid receptor antagonist ( e.g . spironolactone eplerenone ) , aliskiren , vasopressin receptor antagonist ( e.g . tolvaptan ) , oral alkalinize agent ( e.g . sodium potassium citrate Shohl 's solution ) . Note : Patients discontinue ACEinhibitor substitute angiotensin receptor blocker ( ARB ) may eligible rescreened provided medication regimen stable least 1 month renal function stable least 3 month . Any substitution change patient 's medication regimen must do guidance patient 's treating physician . History renal transplant . Known current significant leave ventricular outflow obstruction , obstructive hypertrophic cardiomyopathy significant severe valvular disease prior current echocardiogram . A serum potassium ≤ 3.5 mmol/l ≥ 5.2 mmol/l screening . A previous history previously diagnose renal cystic disease autosomal dominant polycystic kidney disease ( history incidental asymptomatic acquire renal cyst ( ) except ) ; obstructive uropathy ; renal stone ( ) past 2 year ; chronic interstitial nephropathy ; drug induce nephropathy ; residual renal insufficiency follow episode acute kidney injury acute tubular necrosis relate renal atheroembolic disease , septic shock ischemic nephropathy ; renal tubular acidosis require treatment ; nephrotic syndrome nephrotic range proteinuria ; renal artery stenosis .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>